

## SeQuent Scientific Limited

301/A, 'Dosti Pinnacle', Plot No.E7,Road No. 22,  
Wagle Industrial Area, Thane (W),  
Maharashtra, India | [www.sequent.in](http://www.sequent.in)  
CIN: L99999MH1985PLC036685  
Email: info@sequent.in



## SeQuent Scientific completes fund raise of INR 4,000 mn through Qualified Institutional Placement

**Bangalore, May 26, 2015:** SeQuent Scientific Limited, a leading Integrated Pharmaceutical Company with business across Animal Health, niche Human APIs & Analytical Services today announced that it has successfully raised INR 4,000 million pursuant to a Qualified Institutional Placement. The Company has issued 7.47 million equity shares of Rs. 10/- each at Rs. 535/- per share.

### QIP Highlights

- Issued 7,476,635 equity shares at Rs. 535/- per share aggregating to INR 4,000 million.
- The issue which opened for subscription on May 19, 2015 was subscribed to by quality, long term investors who endorsed the vision of the Company of being a **Power House in the Global Animal Health Space**
- The QIP proceeds will be utilized to meet our long term funding requirements including investments in R&D and new markets, capital expenditure and to meet the general business requirements of our Company.

**On the successful completion of the QIP, Mr. Manish Gupta, Managing Director said,** *"SeQuent Scientific, over the last couple of years, has changed the strategy of its business from "Driving growth" to "Creating value". We are focused on becoming a leading, global and integrated company in the animal health segment while also focusing on building a portfolio of niche Human active pharmaceutical ingredients. With the successful completion of capital raise, we now look forward to the next phase of strategic growth with confidence. The overwhelming response to this QIP is a testimony to the confidence that investors have on our differentiated strategy. We thank the investors for reposing their trust in us."*

Axis Capital Limited, Religare Capital Markets Limited and Jefferies India Private Limited were the Book Running Lead Managers to the QIP issue. Khaitan & Co acted as the Indian Legal Counsel to the issue and DSK Legal as the internal legal advisor to the Company.

## About SeQuent Scientific Limited

SeQuent Scientific Limited ("SeQuent") is a leading Integrated Pharmaceutical Company with business across Animal Health, niche Human APIs & Analytical Services.

SeQuent through its subsidiary, Alivira Animal Health Ltd. is emerging as a powerhouse in the global Animal Health business with presence in both the APIs and Formulations, built on a platform of superior quality and compliance.

SeQuent has seven manufacturing facilities based in India and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA amongst others.

The Company is listed on the Bombay Stock Exchange (BSE: 512529) and headquartered in Mumbai, India.

### For Queries, please contact

---

**Manish Gupta**

Managing Director

Tel: +91 22 41114777

[manish@sequent.in](mailto:manish@sequent.in)

**Kannan P R**

Chief Financial Officer

Tel: +91 80 67840327

[Kannan.pr@sequent.in](mailto:Kannan.pr@sequent.in)

**Ankit Gupta**

Christensen Investor Relations

Tel : +91 22 4215 0210

[ankitgupta@christensenir.com](mailto:ankitgupta@christensenir.com)

Legal Disclaimer: Please note that the above press release is for information only and does not constitute an offer of sale of shares. Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Sequent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.